

can recurrence rate by nearly one-third. Aromatase inhibitors have now been studied to improve efficacy in numerous large randomized trials compared with tamoxifen in post-menopausal women, given alone or in an adjuvant setting as first-line therapy for years, sequential therapy sequenced with tamoxifen, or as extended therapy following years of tamoxifen treatment. The publication of this data over the past led the American Society of Clinical Oncology to issue an update to the clinical practice guidelines, which included many trials using aromatase. Despite new data, most recommendations were significantly different from prior guidelines recommending the use of the inhibitor as

Label

0000

0000 0000 0000 0000 0000 0000 0000 0000 0000 0000

0000

0000 0000 0000 0000 0000 0000 0000 0000 0000 0000

0000

0000 0000 0000 0000 0000 0000 0000 0000 0000 0000

0000 0000

0000